The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Genetic targeting in sickle cell disease
Erica Esrick
• 4 Dec 2018
Erica Esrick, MD, of Harvard Medical School, Boston, MA, discusses the inital results of the genetic targeting of BCL11A in sickle cell disease using a shRNAmiR lentiviral vector. This gene therapy showed promising results, as presented here at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
